Morgan Stanley Thinks Talaris Therapeutics’ Stock is Going to Recover

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Talaris Therapeutics (TALSResearch Report), with a price target of $20.00. The company’s shares closed last Monday at $6.96, close to its 52-week low of $5.70.

According to TipRanks.com, Purohit is ranked 0 out of 5 stars with an average return of -25.3% and a 18.9% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Theravance Biopharma, and Foghorn Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Talaris Therapeutics with a $22.50 average price target, implying a 206.5% upside from current levels. In a report issued on May 12, SVB Securities also reiterated a Buy rating on the stock with a $21.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $19.82 and a one-year low of $5.70. Currently, Talaris Therapeutics has an average volume of 42.03K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Read More on TALS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed